179 related articles for article (PubMed ID: 20920993)
21. [Insulin-like growth factor (IGF)-signalling pathway components are potential therapeutic targets in the treatment of human hepatocellular carcinoma].
Nussbaum T; Samarin J; Schirmacher P; Breuhahn K
Verh Dtsch Ges Pathol; 2007; 91():278-85. PubMed ID: 18314625
[TBL] [Abstract][Full Text] [Related]
22. IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.
Dool CJ; Mashhedi H; Zakikhani M; David S; Zhao Y; Birman E; Carboni JM; Gottardis M; Blouin MJ; Pollak M
Endocr Relat Cancer; 2011 Dec; 18(6):699-709. PubMed ID: 21946410
[TBL] [Abstract][Full Text] [Related]
23. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
[TBL] [Abstract][Full Text] [Related]
24. RAV12 accelerates the desensitization of Akt/PKB pathway of insulin-like growth factor I receptor signaling in COLO205.
Li JC; Li R
Cancer Res; 2007 Sep; 67(18):8856-64. PubMed ID: 17875727
[TBL] [Abstract][Full Text] [Related]
25. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy.
Zha J; Lackner MR
Clin Cancer Res; 2010 May; 16(9):2512-7. PubMed ID: 20388853
[TBL] [Abstract][Full Text] [Related]
26. Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice.
Bauer TW; Fan F; Liu W; Camp ER; Yang A; Somcio RJ; Bucana CD; Singh R; Ellis LM
Ann Surg Oncol; 2007 Oct; 14(10):2838-46. PubMed ID: 17653802
[TBL] [Abstract][Full Text] [Related]
27. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
You L; Liu C; Tang H; Liao Y; Fu S
Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
29. IGF-1: old growth factor shines as new drug target.
Garber K
J Natl Cancer Inst; 2005 Jun; 97(11):790-2. PubMed ID: 15928295
[No Abstract] [Full Text] [Related]
30. Simultaneous inhibition of IGF1R and EGFR enhances the efficacy of standard treatment for colorectal cancer by the impairment of DNA repair and the induction of cell death.
Oberthür R; Seemann H; Gehrig J; Rave-Fränk M; Bremmer F; Halpape R; Conradi LC; Scharf JG; Burfeind P; Kaulfuß S
Cancer Lett; 2017 Oct; 407():93-105. PubMed ID: 28823963
[TBL] [Abstract][Full Text] [Related]
31. Role of insulin-like growth factor-1R system in colorectal carcinogenesis.
Donovan EA; Kummar S
Crit Rev Oncol Hematol; 2008 May; 66(2):91-8. PubMed ID: 17977741
[TBL] [Abstract][Full Text] [Related]
32. IGF1R signalling and its inhibition.
Riedemann J; Macaulay VM
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S33-43. PubMed ID: 17259557
[TBL] [Abstract][Full Text] [Related]
33. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.
Tognon CE; Somasiri AM; Evdokimova VE; Trigo G; Uy EE; Melnyk N; Carboni JM; Gottardis MM; Roskelley CD; Pollak M; Sorensen PH
Cancer Res; 2011 Feb; 71(3):1060-70. PubMed ID: 21148487
[TBL] [Abstract][Full Text] [Related]
34. Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy.
Tognon CE; Sorensen PH
Expert Opin Ther Targets; 2012 Jan; 16(1):33-48. PubMed ID: 22239439
[TBL] [Abstract][Full Text] [Related]
35. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C
Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250
[TBL] [Abstract][Full Text] [Related]
37. Treatment of breast cancer cells by IGF1R tyrosine kinase inhibitor combined with conventional systemic drugs.
Hartog H; Van Der Graaf WT; Boezen HM; Wesseling J
Anticancer Res; 2012 Apr; 32(4):1309-18. PubMed ID: 22493363
[TBL] [Abstract][Full Text] [Related]
38. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer.
Cruz JJ; Ocaña A; Del Barco E; Pandiella A
Ann Oncol; 2007 Mar; 18(3):421-30. PubMed ID: 16873430
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer.
Sachdev D; Yee D
J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):27-39. PubMed ID: 16947084
[TBL] [Abstract][Full Text] [Related]
40. Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies.
Yap TA; Olmos D; Molife LR; de Bono JS
Expert Opin Investig Drugs; 2011 Sep; 20(9):1293-304. PubMed ID: 21777167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
